Winston-Salem, NC Apr 25, 2007
Targacept, Inc. (Nasdaq: TRGT) today announced that the company will conduct a conference call and audio webcast at 5:00 p.m. Eastern Daylight Time on Wednesday, May 9, 2007, following the after-market release of its unaudited financial results for the first quarter ended March 31, 2007. J. Donald deBethizy, Ph.D., President and Chief Executive Officer, and Alan A. Musso, Vice President and Chief Financial Officer, will host the call to discuss the company’s first quarter financial results and to provide an update on the company’s product development programs and business activities.
Targacept also announced that Dr. deBethizy will be presenting at the Deutsche Bank 32nd Annual Health Care Conference. Dr. deBethizy is scheduled to give a corporate overview on Wednesday, May 2, 2007 at 9:00 a.m. Eastern Daylight Time at the Mayflower Hotel in Washington, D.C.
Both of these events will be webcast and accessible from the Investor Relations section of Targacept’s website, www.targacept.com. The webcasts will also be available for replay on the company’s website for at least two weeks following the respective events. To ensure a timely connection to a webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time.
The first quarter earnings conference call may be accessed by dialing 866-831-6247 for domestic participants and 617-213-8856 for international callers (reference passcode 51366304). A replay of the conference call may be accessed through May 23, 2007 by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers (reference passcode 70746415).
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics(TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept’s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer’s disease and cognitive deficits in schizophrenia, pain, and depression and anxiety disorders, as well as multiple preclinical programs. Targacept is located in Winston-Salem, North Carolina. Targacept’s news releases are available on its website at www.targacept.com.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Tel: (336) 480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Tel: (508) 419-1555
Email: linnmich@comcast.net